Ignite Creation Date:
2025-12-24 @ 7:38 PM
Ignite Modification Date:
2026-02-25 @ 8:58 PM
Study NCT ID:
NCT02111603
Status:
COMPLETED
Last Update Posted:
2016-05-12
First Post:
2014-04-09
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069472', 'term': 'Colesevelam Hydrochloride'}], 'ancestors': [{'id': 'D000499', 'term': 'Allylamine'}, {'id': 'D000588', 'term': 'Amines'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D000498', 'term': 'Allyl Compounds'}, {'id': 'D000475', 'term': 'Alkenes'}, {'id': 'D006839', 'term': 'Hydrocarbons, Acyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'camilleri.michael@mayo.edu', 'phone': '507-284-6218', 'title': 'Dr. Michael Camilleri', 'organization': 'Mayo Clinic'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': 'Participants were followed for adverse events for the 10 days they were on study.', 'eventGroups': [{'id': 'EG000', 'title': 'Colesevelam', 'description': '1875 mg of Colesevelam orally twice daily for 10 days', 'otherNumAtRisk': 12, 'otherNumAffected': 2, 'seriousNumAtRisk': 12, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 12, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change in Total 48 Hour Fecal Bile Acids (BA) From Baseline in Response to Treatment With Colesevelam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Colesevelam', 'description': '1875 mg of Colesevelam orally twice daily for 10 days'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '1662', 'spread': '234.7', 'groupId': 'OG000'}]}]}, {'title': 'After 10 days treatment with colesevelam', 'categories': [{'measurements': [{'value': '3496', 'spread': '709.2', 'groupId': 'OG000'}]}]}], 'analyses': [{'pValue': '0.012', 'groupIds': ['OG000'], 'ciNumSides': 'TWO_SIDED', 'groupDescription': 'Comparison of on-treatment total fecal bile acid excretion with baseline total fecal bile acid excretion.', 'statisticalMethod': 'Wilcoxon (Mann-Whitney)', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': 'baseline, 10 days', 'description': 'Stool 48 hour collections (for BAs) were collected during baseline before treatment, and then during days 9-10 of the 10 days of colesevelam dosing for fecal BAs. Total fecal BA were measured using HPLC/tandem mass spectrometry.', 'unitOfMeasure': 'uM', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': '13 subjects were accrued. One subject withdrew from the study after the pre-drug activities, but before the treatment activities. Only the 12 participants with complete data at both baseline and after 10 days of treatment are included in the Outcome Measure.'}, {'type': 'SECONDARY', 'title': 'Change in Fasting Serum C4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Colesevelam', 'description': '1875 mg of Colesevelam orally twice daily for 10 days'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '24.7', 'spread': '4.2', 'groupId': 'OG000'}]}]}, {'title': 'After 10 days treatment with colesevelam', 'categories': [{'measurements': [{'value': '72.3', 'spread': '12.2', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline, 10 days', 'description': 'Change in fasting serum C4 from baseline in response to treatment with colesevelam.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': '13 subjects were accrued. One subject withdrew from the study after the pre-drug activities, but before the treatment activities. Only the 12 participants with complete data at both baseline and after 10 days of treatment are included in the Outcome Measure.'}, {'type': 'SECONDARY', 'title': 'Change in Fecal Fat Excretion', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Colesevelam', 'description': '1875 mg of Colesevelam orally twice daily for 10 days'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '6.4', 'spread': '1.2', 'groupId': 'OG000'}]}]}, {'title': 'After 10 days treatment with colesevelam', 'categories': [{'measurements': [{'value': '6.8', 'spread': '0.9', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline, 10 days', 'description': 'Change in fecal fat excretion from baseline in response to treatment with colesevelam', 'unitOfMeasure': 'g/day', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': '13 subjects were accrued. One subject withdrew from the study after the pre-drug activities, but before the treatment activities. Only the 12 participants with complete data at both baseline and after 10 days of treatment are included in the Outcome Measure.'}, {'type': 'SECONDARY', 'title': 'Change in Stool Consistency', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Colesevelam', 'description': '1875 mg of Colesevelam orally twice daily for 10 days'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '4.8', 'spread': '0.3', 'groupId': 'OG000'}]}]}, {'title': 'After 10 days treatment with colesevelam', 'categories': [{'measurements': [{'value': '4.4', 'spread': '0.3', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline, 10 days', 'description': 'The subjects rated their stool consistency using the Bristol Stool Form Scale. The Bristol Stool Form Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the "ideal stools" especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': '13 subjects were accrued. One subject withdrew from the study after the pre-drug activities, but before the treatment activities. Only the 12 participants with complete data at both baseline and after 10 days of treatment are included in the Outcome Measure.'}, {'type': 'SECONDARY', 'title': 'Change in Stool Frequency (Number of Stools Per Week)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Colesevelam', 'description': '1875 mg of Colesevelam orally twice daily for 10 days'}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'value': '17.6', 'spread': '0.4', 'groupId': 'OG000'}]}]}, {'title': 'After 10 days treatment with colesevelam', 'categories': [{'measurements': [{'value': '15.1', 'spread': '1.9', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline, 10 days', 'description': 'Change in stool frequency from baseline in response to treatment with colesevelam.', 'unitOfMeasure': 'Number of stools per week', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': '13 subjects were accrued. One subject withdrew from the study after the pre-drug activities, but before the treatment activities. Only the 12 participants with complete data at both baseline and after 10 days of treatment are included in the Outcome Measure.'}, {'type': 'SECONDARY', 'title': 'Concordance Correlation Coefficients of the Relative Composition of Stool Total and the Main Individual Bile Acids (BA)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Colesevelam', 'description': '1875 mg of Colesevelam orally twice daily for 10 days'}], 'classes': [{'title': 'Total BAs at Baseline', 'categories': [{'measurements': [{'value': '0.53', 'spread': '0.13', 'groupId': 'OG000'}]}]}, {'title': 'Total BAs 48 hour collection after colesevelam', 'categories': [{'measurements': [{'value': '0.54', 'spread': '0.15', 'groupId': 'OG000'}]}]}, {'title': 'CA at Baseline', 'categories': [{'measurements': [{'value': '0.84', 'spread': '0.08', 'groupId': 'OG000'}]}]}, {'title': 'CA 48 hour collection after colesevelam', 'categories': [{'measurements': [{'value': '0.83', 'spread': '0.06', 'groupId': 'OG000'}]}]}, {'title': 'DCA at Baseline', 'categories': [{'measurements': [{'value': '0.68', 'spread': '0.14', 'groupId': 'OG000'}]}]}, {'title': 'DCA 48 hour collection after colesevelam', 'categories': [{'measurements': [{'value': '0.85', 'spread': '0.07', 'groupId': 'OG000'}]}]}, {'title': 'UDCA at Baseline', 'categories': [{'measurements': [{'value': '0.96', 'spread': '0.20', 'groupId': 'OG000'}]}]}, {'title': 'UDCA 48 hour collection after colesevelam', 'categories': [{'measurements': [{'value': '0.54', 'spread': '0.20', 'groupId': 'OG000'}]}]}, {'title': 'CDCA at Baseline', 'categories': [{'measurements': [{'value': '0.88', 'spread': '0.05', 'groupId': 'OG000'}]}]}, {'title': 'CDCA 48 hour collection after colesevelam', 'categories': [{'measurements': [{'value': '0.90', 'spread': '0.06', 'groupId': 'OG000'}]}]}, {'title': 'LCA at Baseline', 'categories': [{'measurements': [{'value': '0.44', 'spread': '0.21', 'groupId': 'OG000'}]}]}, {'title': 'LCA 48 hour collection after colesevelam', 'categories': [{'measurements': [{'value': '0.88', 'spread': '0.07', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline, 10 days', 'description': 'Stool 48 hour collections (for BAs) were collected during baseline before treatment, and then during days 9-10 of the 10 days of colesevelam dosing for fecal BAs. Relative composition of the main individual bile acids (cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA) and ursodeoxycholic acid (UDCA)) in 48 hour stool collection after colesevelam treatment were compared to baseline values.\n\nThe concordance correlation coefficient (rc) measures agreement between two variables. The concordance correlation satisfies -1 ≤ rc ≤ +1. A value of rc = +1 corresponds to perfect agreement. A value of rc = -1 corresponds to perfect negative agreement, and a value of rc = 0 corresponds to no agreement.', 'unitOfMeasure': 'concordance correlation coefficient', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': '13 subjects were accrued. One subject withdrew from the study after the pre-drug activities, but before the treatment activities. Only the 12 participants with complete data at both baseline and after 10 days of treatment are included in the Outcome Measure.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Colesevelam', 'description': '1875 mg of Colesevelam orally twice daily for 10 days'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '13'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '12'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}]}]}], 'recruitmentDetails': 'Participants were recruited from the Mayo Clinic in Rochester, Minnesota.', 'preAssignmentDetails': '13 subjects were accrued. One subject withdrew from the study after the pre-drug activities, but before the treatment activities.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Colesevelam', 'description': '1875 mg of Colesevelam orally twice daily for 10 days'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '43.1', 'spread': '3.7', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '11', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '12', 'groupId': 'BG000'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Mean Body Mass Index (BMI)', 'classes': [{'categories': [{'measurements': [{'value': '31.1', 'spread': '2.4', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'kg/m^2', 'dispersionType': 'STANDARD_DEVIATION'}], 'populationDescription': '13 subjects were accrued. One subject withdrew from the study after the pre-drug activities, but before the treatment activities.'}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 13}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2014-04'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-04', 'completionDateStruct': {'date': '2015-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-04-08', 'studyFirstSubmitDate': '2014-04-09', 'resultsFirstSubmitDate': '2015-10-16', 'studyFirstSubmitQcDate': '2014-04-10', 'lastUpdatePostDateStruct': {'date': '2016-05-12', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2015-12-18', 'studyFirstPostDateStruct': {'date': '2014-04-11', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2016-01-27', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in Total 48 Hour Fecal Bile Acids (BA) From Baseline in Response to Treatment With Colesevelam', 'timeFrame': 'baseline, 10 days', 'description': 'Stool 48 hour collections (for BAs) were collected during baseline before treatment, and then during days 9-10 of the 10 days of colesevelam dosing for fecal BAs. Total fecal BA were measured using HPLC/tandem mass spectrometry.'}], 'secondaryOutcomes': [{'measure': 'Change in Fasting Serum C4', 'timeFrame': 'baseline, 10 days', 'description': 'Change in fasting serum C4 from baseline in response to treatment with colesevelam.'}, {'measure': 'Change in Fecal Fat Excretion', 'timeFrame': 'baseline, 10 days', 'description': 'Change in fecal fat excretion from baseline in response to treatment with colesevelam'}, {'measure': 'Change in Stool Consistency', 'timeFrame': 'baseline, 10 days', 'description': 'The subjects rated their stool consistency using the Bristol Stool Form Scale. The Bristol Stool Form Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the "ideal stools" especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea.'}, {'measure': 'Change in Stool Frequency (Number of Stools Per Week)', 'timeFrame': 'baseline, 10 days', 'description': 'Change in stool frequency from baseline in response to treatment with colesevelam.'}, {'measure': 'Concordance Correlation Coefficients of the Relative Composition of Stool Total and the Main Individual Bile Acids (BA)', 'timeFrame': 'baseline, 10 days', 'description': 'Stool 48 hour collections (for BAs) were collected during baseline before treatment, and then during days 9-10 of the 10 days of colesevelam dosing for fecal BAs. Relative composition of the main individual bile acids (cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA) and ursodeoxycholic acid (UDCA)) in 48 hour stool collection after colesevelam treatment were compared to baseline values.\n\nThe concordance correlation coefficient (rc) measures agreement between two variables. The concordance correlation satisfies -1 ≤ rc ≤ +1. A value of rc = +1 corresponds to perfect agreement. A value of rc = -1 corresponds to perfect negative agreement, and a value of rc = 0 corresponds to no agreement.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Diarrhea Predominant Irritable Bowel Syndrome']}, 'referencesModule': {'references': [{'pmid': '25594801', 'type': 'RESULT', 'citation': 'Camilleri M, Acosta A, Busciglio I, Boldingh A, Dyer RB, Zinsmeister AR, Lueke A, Gray A, Donato LJ. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2015 Mar;41(5):438-48. doi: 10.1111/apt.13065. Epub 2015 Jan 16.'}]}, 'descriptionModule': {'briefSummary': "The investigators' hypothesis is that therapy with Colesevelam, reduces fecal bile acid excretion in patients with Irritable Bowel Syndrome (IBS)-diarrhea with prior evidence of increased fecal 48 hour total bile acid excretion. The investigators aim to study the ability of the HPLC assay for fecal bile acids to demonstrate responsiveness after treatment with Colesevelam.", 'detailedDescription': "This study will evaluate whether Colesevelam, a bile acid sequestrant, is able to reduce fecal bile acids and improve bowel function in patients with IBS-diarrhea and Mayo's HPLC method can demonstrate a response to the Colesevelam.\n\nThe study design will be a single center, unblinded, single dose trial to study the ability to identify the effect of taking 1875 mg (3 tablets \\[625 mg/tablet\\]) of Colesevelam orally twice daily for ten days on fasting serum 7alphaC4 and total 48 hour fecal bile acid excretion. Stool and fasting serum samples will be collected predose and during final 48 hours' dosing for assessment. Participants will also fill out an 8-day stool diary assessing frequency, consistency, ease of passage of bowel movements before and during treatment with Colesevelam."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Patients with IBS-diarrhea with prior evidence of increased fecal 48 hour total bile acid and increased fasting serum 7alphaC4 who meet the following:\n\nINCLUSION CRITERIA\n\n* Bowel disease questionnaire (BDQ) - IBS symptoms: Positive by Rome lll criteria\n* No restrictions on Hospital Anxiety/Depression Score (HADS).\n* Gender: Men or women. Women of childbearing potential will have a negative pregnancy test before initiation of medication.\n\nEXCLUSION CRITERIA\n\n* Use of drugs or agents within the past 1 week or planned use in the subsequent 2 weeks during the study period (Birth control pill, estrogen replacement therapy, and thyroxine replacement are permissible exceptions):\n\n * Agents that alter GI transit including opioids, narcotics, anticholinergics, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRI) antidepressants.\n * Analgesic drugs including opiates, nonsteroidal anti-inflammatory drugs (NSAID), cyclooxygenase-2 (COX 2) inhibitors\n * Intake of medication that could interfere with the interpretation of the study.\n* Female subjects who are pregnant or breast-feeding. Females must be either surgically sterilized, postmenopausal (\\>12 months since last menses), or, if of childbearing potential, using reliable methods of contraception as determined by the physician.\n* Abdominal surgery (except Appendectomy)\n* Patients with known chronic liver disease or history of elevated aspartate aminotransferase (AST)/ alanine transaminase (ALT) 2.0 X upper limit of normal.\n\n * Bile acid (BA) synthesis and possible false positive or negative fecal bile acid or serum 7alpha-hydroxy-4-cholesten-3-one (7alphaC4) result. If there is no AST or ALT values in the medical record, the study physicians will determine if the tests need to be run.'}, 'identificationModule': {'nctId': 'NCT02111603', 'briefTitle': 'Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids', 'organization': {'class': 'OTHER', 'fullName': 'Mayo Clinic'}, 'officialTitle': 'Ability of Mayo Clinic HPLC Method to Measure Fecal Bile Acids to Demonstrate Response to Colesevelam in Patients With Diarrhea Predominant Irritable Bowel Syndrome', 'orgStudyIdInfo': {'id': '14-000384'}, 'secondaryIdInfos': [{'id': 'R01DK092179', 'link': 'https://reporter.nih.gov/quickSearch/R01DK092179', 'type': 'NIH'}, {'id': 'UL1TR000135', 'link': 'https://reporter.nih.gov/quickSearch/UL1TR000135', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'OTHER', 'label': 'Colesevelam', 'description': '1875 mg of Colesevelam orally twice daily for 10 days', 'interventionNames': ['Drug: Colesevelam']}], 'interventions': [{'name': 'Colesevelam', 'type': 'DRUG', 'otherNames': ['Welchol'], 'description': 'Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days', 'armGroupLabels': ['Colesevelam']}]}, 'contactsLocationsModule': {'locations': [{'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Mayo Clinic in Rochester', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}], 'overallOfficials': [{'name': 'Michael Camilleri, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Mayo Clinic'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Data already published in PMID: 25594801'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Mayo Clinic', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'MD', 'investigatorFullName': 'Michael Camilleri', 'investigatorAffiliation': 'Mayo Clinic'}}}}